Movalis (Meloxicam)

Meloxicam selectively blocks the COX‑2 enzyme, which reduces the production of prostaglandins—chemical mediators that cause inflammation, pain, and fever. By lowering prostaglandin levels, the drug diminishes swelling and discomfort while preserving COX‑1 activity that protects the stomach lining.

The appropriate dose of Movalis is determined by the prescribing clinician based on the patient’s condition, severity, and overall health. Dosage may vary, and the prescriber will provide specific instructions for each individual case.

Movalis is classified as pregnancy category B1, indicating no proven risk in animal studies but limited human data. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Movalis product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a higher degree of COX‑2 selectivity, which may reduce the incidence of gastrointestinal side effects while still providing effective anti‑inflammatory and analgesic action. However, individual response and safety profiles vary, so clinicians choose the agent best suited to each patient’s risk factors.

Movalis should be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking the solution. Do not store at room temperature for prolonged periods.

Movalis is supplied as an injectable solution for intramuscular injection. A qualified healthcare professional administers the dose into a suitable muscle, typically the gluteal or deltoid region, following aseptic technique and the prescriber’s dosing instructions.

Serious risks include gastrointestinal bleeding or ulceration, severe cardiovascular events such as heart attack or stroke, liver injury, acute renal failure, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for any signs of these conditions.

Movalis is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, patients with severe heart failure, and anyone who has experienced a serious allergic reaction to similar medications. It should also be used with caution in patients with impaired kidney or liver function.